Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 1 Aug 2020

Cao Zhi-Xing, Guo Chuan-Jie, Song Xiaominting, He Jun-Lin, Tan Lu, Yu Si, Zhang Ruo-Qi, Peng Fu, Peng Cheng, Li Yu-Zhi

Abstract excerpt

Erlotinib has potential therapeutic effect on acute myeloid leukemia (AML) in patients, but the mechanism is not clear. Effective tumor biomarkers for erlotinib in the treatment of AML remain poorly defined. Here, we demonstrate that erlotinib in vitro significantly inhibits the growth of the FLT3-ITD mutant AML cell MV4-11 and Ba/F3-FLT3-ITD cell via targeting FLT3, a certified valid target for the effective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to src-Family Kinases

Share to Tandem Repeat Sequences

Share to THP-1 Cells

Source

Identifiers

PMID: 32543003
DOI: 10.1096/fj.201902922RR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn.PMID 32543003Read ↗

Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-MycSemantic proximity Read ↗

Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth through inhibiting SETD1A/AKT-mediated DNA damage responseSemantic proximity Read ↗

Successful treatment with gilteritinib for popliteal extramedullary relapse of FLT-3-ITD acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation : a case report and literature reviewSemantic proximity Read ↗

Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.Semantic proximity Read ↗

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Semantic proximity Read ↗

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia.Semantic proximity Read ↗

Anlotinib Exerts Potent Antileukemic Activities in B-Cell Acute Lymphoblastic Leukemia Via Attenuation of PI3K/AKT/mTOR Signaling CascadeSemantic proximity Read ↗

Post-HSCT maintenance treatment using entrectinib for an AML patient accompanied ETV6-NTRK3: a case reportSemantic proximity Read ↗

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.Semantic proximity Read ↗

Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.Semantic proximity Read ↗

FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.Semantic proximity Read ↗

FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.